Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes  by Lee, Hans C. et al.
Biol Blood Marrow Transplant 21 (2015) 1948e1954Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgMixed T Lymphocyte Chimerism after Allogeneic
Hematopoietic Transplantation Is Predictive for Relapse
of Acute Myeloid Leukemia and Myelodysplastic SyndromesHans C. Lee 1, Rima M. Saliba 2, Gabriela Rondon 2, Julianne Chen 2, Yasmeen Charafeddine 2,
L. Jeffrey Medeiros 3, Gheath Alatrash 2, Borje S. Andersson 2, Uday Popat 2, Partow Kebriaei 2,
Stefan Ciurea 2, Betul Oran 2, Elizabeth Shpall 2, Richard Champlin 2,*
1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas
2Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TexasArticle history:
Received 6 May 2015
Accepted 6 July 2015
Key Words:
Chimerism
Relapse
Acute myeloid leukemia
Myelodysplastic syndromeFinancial disclosure: See Acknowl
* Correspondence and reprint re
Texas MD Anderson Cancer Cente
TX 77030.
E-mail address: rchampli@mda
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
Chimerism testing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute
myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represents a promising tool for predicting
disease relapse, although its precise role in this setting remains unclear. We investigated the predictive value
of T lymphocyte chimerism analysis at 90 to 120 days after allo-HSCT in 378 patients with AML/MDS who
underwent busulfan/ﬂudarabine-based myeloablative preparative regimens. Of 265 (70%) patients with
available T lymphocyte chimerism data, 43% of patients in ﬁrst or second complete remission (CR1/CR2) at the
time of transplantation had complete (100%) donor T lymphocytes at day þ90 to þ120 compared with 60% of
patients in the non-CR1/CR2 cohort (P ¼ .005). In CR1/CR2 patients, donor T lymphocyte chimerism  85% at
day þ90 to þ120 was associated with a higher frequency of 3-year disease progression (29%; 95% conﬁdence
interval [CI], 18% to 46% versus 15%; 95% CI, 9% to 23%; hazard ratio [HR], 2.1; P ¼ .04). However, in the more
advanced, non-CR1/CR2 cohort, mixed T lymphocyte chimerism was not associated with relapse (37%; 95% CI,
20% to 66% versus 34%; 95% CI, 25% to 47%; HR, 1.3; P ¼ .60). These ﬁndings demonstrate that early T
lymphocyte chimerism testing at day þ90 to þ120 is a useful approach for predicting AML/MDS disease
recurrence in patients in CR1/CR2 at the time of transplantation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Although allogeneic hematopoietic transplantation (allo-
HSCT) represents a potential curative therapy for patients
with acute myeloid leukemia (AML) and myelodysplastic
syndromes (MDS), the major cause of treatment failure is
disease recurrence [1]. The ability to predict relapse before
detectable morphologic recurrence may allow for preemp-
tive interventions, such as immune modulation, donor
lymphocyte infusion (DLI), or initiation of hypomethylating
agents, in high-risk patients to potentially augment graft-
versus-leukemia (GVL) effects [2-5]. Post-transplantation
peripheral blood chimerism analysis, which quantiﬁes theedgments on page 1953.
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ty for Blood and Marrow Transplantation.relative levels of donor and recipient hematopoiesis, repre-
sents 1 potential tool to predict disease recurrence in
the post-transplantation setting, especially in patients
without speciﬁc cytogenetic, molecular, or immunopheno-
typic leukemic signatures that allow more direct monitoring
of disease [6].
There have been a number of studies that have investi-
gated the efﬁcacy of chimerism analysis in predicting dis-
ease relapse, especially with the advent of more sensitive
PCR-based methods and lineage-speciﬁc analyses to detect
donor/recipient hematopoiesis [7]. However, the use of
chimerism analysis to identify AML patients at high risk of
relapse after allo-HSCT remains controversial. Several
studies have suggested that mixed donor and recipient
chimerism or chimerism kinetics (full donor chimerism to
mixed chimerism) can predict disease recurrence [8-12],
whereas other studies have suggested that such analyses
cannot be used reliably [13-15]. Moreover, a substantial
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populations or have been limited by small patient cohorts
or disease heterogeneity inclusive of all leukemia subtypes
with variable kinetics of relapse. Results may also vary
depending on the preparative regimen. For example, the
combination of busulfan and ﬂudarabine, which has been
widely used as a myeloablative preparative regimen for
myeloidmalignancies [16-23], is associated with a relatively
high rate of mixed T lymphocyte chimerism [24]. We sought
to examine the effect of mixed T lymphocyte chimerism on
the risk of relapse after transplantation in patients with
AML or MDS. In this single-institution retrospective anal-
ysis, we report the largest study to date to our knowledge
investigating the potential utility of T lymphocyte chime-
rism analysis between post-transplantation day þ90
to þ120 in predicting relapse for AML/MDS patients after
myeloablative allo-HSCT using the busulfan-ﬂudarabine
preparative regimen and tacrolimus/methotrexate graft-
versus-host-disease (GVHD) prophylaxis.
PATIENTS AND METHODS
Patient Eligibility
Patients who underwent allo-HSCT for AML or MDS on 5 separate
sequential clinical protocols involving myeloablative conditioning with
busulfan and ﬂudarabine at the University of Texas MD Anderson Cancer
Center between 2001 and 2011 were included in this retrospective analysis.
Informed consentwas obtained from each patient per institutional guidelines
before enrollment in each clinical trial. The institutional review board also
reviewed and approved this retrospective analysis. All patients received
myeloablative conditioning consisting of ﬂudarabine 40 mg/m2 with
busulfan 130 mg/m2 daily for 4 days or with busulfan given with pharma-
cokinetic dose adjustment, targeting a drug concentration area under the
curve of 6000 mM  minute. Post-transplantation GVHD prophylaxis
consisted of methotrexate 5 mg/m2 on days 1, 3, 6, and 11 and tacrolimus,
which was tapered after 4 to 6 months. Patients receiving unrelated donor
transplants received antithymocyte globulin (Thymoglobulin; Genzyme
Corporation, Cambridge, MA) 4.5 mg/kg pretransplantation in divided doses.
Chimerism Testing
Peripheral blood chimerism analysis was performed using 8 highly
polymorphic microsatellite markers (Integrated DNA Technologies, Coral-
ville, IA) in a multiplex PCR assay. Each marker was labeled with a ﬂuores-
cent tag that allows size separation by using capillary electrophoresis in an
ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). Data are
presented as peaks, and the area under the curve represents the percentage
of host-versus-donor hematopoiesis. In addition to looking at overall
chimerism status, lineage-speciﬁc analysis was also performed by sepa-
rating out myeloid and T lymphocyte cell populations using the RoboSep
Magnetic Cell System and the EasySep whole blood CD3 positive or myeloid
selection (anti-CD14 þ CD66b) kits (Stem Cell Technologies, Vancouver, BC,
Canada).
Endpoints and Statistical Analysis
The primary objective of the study was to assess the rate of disease
progression according to peripheral blood T lymphocyte chimerism eval-
uated between day þ90 to þ120 after transplantation. Leukemic disease
progressionwas deﬁned by morphology as the appearance of >5% blasts on
bone marrow aspirate smears. Only patients who were alive and free
of disease progression at day þ120 after transplantation were eligible for
this assessment. The cumulative incidence of disease progression after
day þ120 (landmark analysis) was estimated considering death before
disease progression as a competing risk. Predictors of disease progression
were assessed using Cox’s proportional regression analysis. Predictors
included were chimerism status, age, gender, cytogenetic risk group,
modiﬁed European Leukemia Net (ELN) risk stratiﬁcation [25], donor type,
cell type, and ﬁxed or adjusted busulfan dose. Because of the limited
number of patients who had both NPM1 and FLT3-ITD mutation status
reported in this study, ELN classiﬁcation was modiﬁed to categorize cyto-
genetically normal patients only on the basis of FLT3-ITD mutation status.
Patient and transplantation characteristics were compared using Fisher’s
exact and chi-squared test for categorical variables and Mann-Whitney’s
test for continuous variables. Statistical signiﬁcance was deﬁned at the .05
level. Statistical analysis was performed using STATA 11.0 (StataCorp,
College Station, TX).RESULTS
Patient Characteristics
A total of 378 consecutive patients who were alive and
without evidence of disease progression on day þ120 after
allo-HSCTmet the eligibility criteria andwere included in the
study. Characteristics of these patients are delineated in
Table 1 and characteristics of patients who were excluded
from the study because of disease progression before
day þ120 are provided in Supplemental Table S1. In the
study-eligible population, 305 (81%) patients had AML and
73 (19%) patients had MDS. The median age was 48 years,
and 224 (59%) patients underwent transplantation in ﬁrst or
second complete remission (CR1/CR2). One hundred ﬁfty-
eight patients were not in remission or beyond CR2 (non-
CR1/CR2). Peripheral blood stem cells were used in 242 (64%)
patients and bone marrow was used in 36% patients. Over
one half (52%) of all patients received a matched related
donor transplant. Among the 378 eligible patients in the
study, peripheral blood T lymphocyte and myeloid donor
chimerism data between dayþ90 to þ120 were available for
265 (70%) and 286 (76%) patients, respectively.
Mixed T Lymphocyte Chimerism and Disease Status at
Transplantation
There was a signiﬁcant association between disease sta-
tus at transplant and day þ90 to þ120 donor T lymphocyte
chimerism. Of 164 patients in the CR1/CR2 cohort, 43% of
patients had complete donor T lymphocyte chimerism
compared with 60% of patients in the non-CR1/CR2 cohort
(P ¼ .005). Most (90%) patients in the CR1/CR2 and non-CR1/
CR2 cohorts achieved complete (100%) or near complete
(99%) donor myeloid chimerism by day þ90 to þ120
(Table 2). Because of the high rates of full donor myeloid
chimerism by day þ90 to þ120 in all patients, signifying the
low value of myeloid chimerism at this time point, subse-
quent analyses focused solely on the impact of T lymphocyte
chimerism and post-transplantation disease progression.
Moreover, given the differences in donor T lymphocyte
chimerism based on disease status at transplantation, pre-
dictors of disease progression were analyzed separately
for CR1/CR2 and non-CR1/CR2 patients at the time of
transplantation.
Age, donor type, and a history of grade  2 acute GVHD,
and cytogenetics risk group were comparable (P > .10) be-
tween the CR1/CR2 and non-CR1/CR2 groups (Table 1).
Among CR1/CR2 patients with T lymphocyte chimerism data
available, 40% were greater than 50 years of age, 56% had a
related donor transplantation, 26% had a history of grade  2
acute GVHD, and 30% had poor risk, 57% intermediate risk,
10% good risk, and 2% unknown risk cytogenetics. The cor-
responding proportions in the non-CR1/CR2 groupwere 44%,
44%, 30%, 36%, 43%, 19%, and 3%, respectively.
Predictors of Disease Progression
CR1/CR2 cohort
Based on the distribution of the percentages of donor T
lymphocyte chimerism in the CR1/CR2 cohort, T lympho-
cyte chimerism was further subdivided by the following
intervals: 100%, 96% to 99%, 86% to 95%, 76% to 85%, 51% to
75%, and 50%. The rate of disease progression was
comparably low in patients with 100%, 96% to 99% or 86% to
95%, and comparably high in patients with 76% to 85%, 51%
to 75%, or 50% (Table S2). Based on these ﬁndings, 85%
was chosen as the cut-off for subsequent analyses of
T lymphocyte donor chimerism. In landmark analysis, the
Table 1
Patient Characteristics
Characteristic Overall T Lymphocyte Chimerism
Available
T Lymphocyte Chimerism
Available CR1/CR2
T Lymphocyte Chimerism
Available Non-CR1/CR2
Total patients 378 265 164 101
Sex
Female 185 (49) 125 (47) 75 (46) 50 (50)
Male 193 (51) 140 (53) 89 (54) 51 (50)
Age
50 231 (61) 156 (59) 99 (60) 57 (56)
>50 147 (39) 109 (41) 65 (40) 44 (44)
Diagnosis
AML 305 (81) 186 (70) 152 (93) 61 (60)
MDS 73 (19) 79 (30) 12 (7) 40 (40)
Disease status at transplantation
CR1 158 (42) 119 (45)
CR2 66 (17) 45 (17)
Not CR 154 (41) 101 (38)
Cytogenetics
Good risk 50 (13) 36 (14) 17 (10) 19 (19)
Intermediate risk 196 (52) 136 (51) 93 (57) 43 (43)
Poor risk 121 (32) 86 (32) 50 (30) 36 (36)
Unknown 11 (3) 7 (3) 4 (2) 3 (3)
FLT3 ITD mutation
Yes 45 (12) 36 (14) 31 (19) 5 (5)
No 224 (59) 161 (61) 95 (58) 66 (65)
N/A 109 (29) 68 (26) 38 (23) 30 (30)
Modiﬁed ELN classiﬁcation
Favorable 114 (30) 82 (31) 50 (30) 32 (32)
Intermediate 1* 32 (8) 27 (10) 24 (15) 5 (5)
Intermediate 2 75 (20) 53 (20) 38 (23) 15 (15)
Adverse 85 (22) 60 (23) 29 (18) 31 (31)
Cg normal, FLT3 ITD N/A 56 (15) 30 (11) 16 (10) 14 (14)
Cg N/A 16 (4) 11 (4) 7 (4) 4 (4)
Stem cell source
Bone marrow 135 (36) 92 (35) 54 (33) 38 (38)
Peripheral blood 242 (64) 173 (65) 110 (67) 63 (63)
Cord blood 1 (0) 0 (0) 0 (0) 0 (0)
Donor type
Matched related donor 195 (52) 137 (52) 92 (56) 45 (44)
Other 183 (48) 128 (48) 72 (44) 56 (55)
GVHD prophylaxis
Tacrolimus/methotrexate 335 (89) 237 (89) 149 (91) 88 (87)
Tacrolimus/methotrexate/pentostatin 42 (11) 28 (11) 15 (9) 13 (13)
Other 1 (0) 0 (0) 0 (0) 0 (0)
N/A indicates not available; Cg, cytogenetics.
Data presented are n (%), unless otherwise indicated.
* Intermediate-I included only FLT3-ITD mutant patients because of limited number of patients with both NPM1 and FLT3-ITD mutation reported.
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transplantation was signiﬁcantly higher (29%; 95% conﬁ-
dence interval [CI], 18% to 46%) in the85% group compared
with the >85% group (15%; 95% CI, 9% to 23%; hazard ratio
[HR], 2.1; P ¼ .04) (Table S4, Figure 1A). Patients classiﬁed as
adverse according to the modiﬁed ELN risk stratiﬁcation
system had a signiﬁcantly higher rate of disease progression
(HR, 3.0; P¼ .004). Nevertheless, on bivariate analysis,85%Table 2
Myeloid and T Lymphocyte Chimerism at Day þ90 to þ120 according to
Disease Status at Transplantation
CR1/CR2 Non-CR1/CR2 P Value
% Donor T lymphocyte
chimerism
n ¼ 164 (%) n ¼ 101 (%)
100 70 (43%) 61 (60%) .005
86-99 49 (30%) 21 (21%) Ref.
85 45 (27%) 19 (19%) Ref.
% Donor myeloid chimerism n ¼ 179 (%) n ¼ 107 (%)
100 120 (67%) 80 (75%) .20
99 44 (25%) 13 (12%) Ref.
98 15 (8%) 14 (13%) Ref.
Ref. indicates reference.donor T lymphocyte chimerism at day þ90 to þ120
remained an independent predictor of disease progression
regardless of adverse modiﬁed ELN risk (HR, 2.4; P ¼ .02).
None of the remaining patient or transplantation charac-
teristics assessed (age, gender, cytogenetic risk group,
donor type, stem cell source, and ﬁxed or adjusted busulfan
dose) were signiﬁcantly associated with the rate of disease
progression in the CR1/CR2 cohort (data not shown).
Non-CR1/CR2 cohort
Using the same categorization of chimerism as described
for the CR1/CR2 cohort, there was no signiﬁcant association
between mixed T lymphocyte donor chimerism and the rate
of disease progression by 3 years after transplantation in the
non-CR1/CR2 cohort (Tables S3 and S4). In a landmark
analysis, the cumulative incidence of disease progression at
3 years after transplantation was 37% (95% CI, 20% to 66%) in
the 85% and 34% (95% CI, 25% to 47%) in the >85% group
(HR, 1.3; P ¼ .60) (Figure 1B). When examined at earlier time
points before the 3-year landmark analysis, therewas a trend
towards increased rate of disease progression in patients
with 85% T lymphocyte chimerism at 6 months and 1 year,
although this did not reach statistical signiﬁcance (Table S5).
Figure 1. Cumulative incidence of disease progression at 3 years after transplantation based on T lymphocyte chimerism in (A) CR1/CR2 patients at transplantation
and (B) non-CR1/CR2 patients at transplantation.
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ELN stratiﬁcation system had higher rates of disease pro-
gression, although this did not reach statistical signiﬁcance
(HR, 2.1; P ¼ .06). On bivariate analysis, neither modiﬁed
ELN risk stratiﬁcation nor day þ90 to þ120 T lymphocyte
chimerismwere signiﬁcant predictors of disease progression.
Moreover, age, gender, cytogenetic risk group, donor type,
cell type, and ﬁxed or adjusted busulfan dose were not
associated with the rate of disease progression in the non-
CR1/CR2 cohort. The overall survival related to T-cell
chimerism is shown in (Figure 2).
T Lymphocyte Chimerism, GVHD, and Disease Progression
There was no signiﬁcant difference in the history of acute
GVHD based on donor T lymphocyte chimerism levels at
day þ90 to þ120 when stratiﬁed at the 85% cut-off point
(Table 3). Grade II to IV acute GVHD occurred in 15 of 64
patients (23%) with85% T lymphocyte chimerism compared
with in 58 of 201 patients (29%) with >85% T lymphocyte
chimerism (P ¼ .40). A history of grade II to IV or III and IV
acute GVHD was not associated with the rate of diseaseFigure 2. Overall survival at 3 years after transplantation based on T lymphocyte chim
at transplantation.progression (Table 4). Likewise, the frequency of chronic
GVHD did not differ signiﬁcantly based on T lymphocyte
chimerism levels at day þ90 to þ120. The prevalence of
chronic GVHD by dayþ90 toþ120was 9% in85% group and
11% in the >85% group (P ¼ .70) (Table 3); and the incidence
of chronic GVHD after day þ90 to þ120 was 52% and 59%
(P ¼ .90) (Table 5) in the 2 groups, respectively. Because of
the known associations between complete donor T lympho-
cyte chimerism and GVHD [26-28], which may inﬂuence
relapse risk, we evaluated the impact of chronic GVHD on
disease progression as time-dependent covariates. Indeed,
chronic GVHD was associated with lower rate of disease
progression regardless of disease status at transplantation.
However, this association was only statistically signiﬁcant in
CR1/CR2 patients (P¼ .02) and not in the non-CR1/CR2 cohort
(P ¼ .20). On bivariate analysis taking into consideration both
chronic GVHD as a time-dependent variable and mixed
T lymphocyte chimerism  85% (Table 4), both factors
remained signiﬁcant predictors of disease progression for the
CR1/CR2 group (P ¼ .02, P ¼ .03, respectively) but not in the
non-CR1/CR2 cohort (P ¼ .20, P ¼ .60, respectively).erism in (A) CR1/CR2 patients at transplantation and (B) non-CR1/CR2 patients
Table 3
Correlation of Day þ90 to þ120 T Lymphocyte Chimerism with GVHD
T Lymphocyte
Chimerism  85%
n ¼ 64 (%)
T Lymphocyte
Chimerism > 85%
n ¼ 201 (%)
P
History of aGVHD
Grade 1 14 (22) 55 (27)
Grades 2-4 15 (23) 58 (29) .40
Grade 2 13 (20) 44 (22)
Grades 3-4 2 (3) 14 (7) .20
cGVHD before day þ120 6 (9) 22 (11) .70
aGVHD indicates acute graft-versus-host-disease; cGVHD, chronic graft-
versus-host-disease.
Table 5
Correlation of Day þ90 to þ120 T Lymphocyte Chimerism with 3-Year Cu-
mulative Incidence of cGVHD
T Lymphocyte
Chimerism 
85%
T Lymphocyte
Chimerism >
85%
% 3-Year
Cumulative
Incidence*
(95% CI)
% 3-Year
Cumulative
Incidence*
(95% CI) HR 95% CI P
cGVHD overall 52% (41-63) 59% (53-66) .8 .6-1.2 .40
cGVHD in
CR1/CR2
58% (45-74) 61% (53-71) .94 .6-1.5 .80
cGVHD in
non-CR1/CR2
37% (20-66) 56% (46-68) .6 .2-1.4 .20
* Accounting for disease progression or death before cGVHD as
competing risks.
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In this analysis, we report the largest study to date to
our knowledge investigating the role of chimerism testing
between after transplantation day þ90 to þ120 in predict-
ing disease progression in AML/MDS patients. Several
studies have evaluated the role of chimerism analysis in
predicting disease recurrence in AML/MDS after trans-
plantation, yet these reports have often been limited by
small patient cohorts [29,30], heterogeneous disease pop-
ulations with variable kinetics of relapse [10,31], or lack of
lineage-speciﬁc analyses [32,33]. This study focused on
patients receiving a uniform, widely used, busulfan-
ﬂudarabine myeloablative preparative regimen, which is
known to have a relatively high rate of mixed lymphocyte
chimerism [24]. All patients received tacrolimus/metho-
trexate post-transplantation immunosuppressive therapy.
We hypothesized that a higher degree of mixed lymphocyte
peripheral blood chimerism may be associated with an
increased risk of leukemia relapse after transplantation.
We found a signiﬁcant association between disease
status at transplantation and the kinetics of T lymphocyte
engraftment, as a lower proportion of patients in CR1/CR2 at
transplantation had complete T lymphocyte engraftment at
dayþ90 to þ120 compared with in the non-CR1/CR2 cohort.
This is likely explained by the greater pretransplantation
chemotherapy exposure in the non-CR1/CR2 patients,
resulting in greater cumulative immunosuppression, which
would facilitate donor engraftment. This is consistent with
previous reports that demonstrated a signiﬁcant association
between the number of pretransplantation chemotherapy
regimens and T lymphocyte engraftment kinetics [34-37].
In contrast, nearly all patients who were alive and free of
disease at the time of chimerism testing achieved complete
donor myeloid chimerism by day þ90 to þ120, regardless ofTable 4
Impact of aGVHD and cGVHD on Disease Progression
CR1/CR2
n ¼ 164
Non-CR1/CR2
n ¼ 101
HR 95% CI P HR 95% CI P
History of aGVHD II-IV 1.7 .8-3.6 .2 .5 .2-1.2 .10
History of aGVHD III-IV No
events*
.30 1.2 .3-5.0 .80
cGVHD (as time-dependent
variable)
.3 .1-.8 .02 .6 .3-1.3 .20
Bivariate analysis cGVHD and
T lymphocyte chimerism
cGVHD (as time-dependent
variable)
.3 .1-.8 .02 .6 .3-1.3 .20
Chimerism  85% 2.2 1.1-4.6 .03 1.2 .5-2.9 .60
* No events in 2 patients with grade III-IV aGVHD.disease status at transplantation. Overall, T lymphocyte
chimerism lagged behind the myeloid compartment, which
is consistent with a prior study evaluating lineage-speciﬁc
chimerism kinetics using a busulfan-ﬂudarabine condition-
ing regimen [24]. Some reports have also suggested that
conditioning regimens with busulfan, such as those used in
this study, may result in less lymphodepletion compared
with melphalan-based regimens [37], but a recent study
reported no difference in T lymphocyte engraftment kinetics
between the 2 agents [38]. Taken together, these studies
imply that the rates of lymphocyte chimerism vary for
different preparative regimens, and that the predictive value
of mixed lymphocyte chimerismmay also vary depending on
the type and intensity of conditioning, use of antieT cell
antibodies, or T cell depletion of the graft.
As most patients achieved complete or near complete
donor myeloid chimerism by post-transplantation day þ90
to þ120, our analysis focused on the impact of mixed T
lymphocyte chimerism on disease progression. T lymphocyte
donor chimerism 85% was a signiﬁcant predictor of disease
progression in CR1/CR2 patients. In contrast, mixed T
lymphocyte chimerism did not signiﬁcantly affect disease
progression rates in the non-CR1/CR2 cohort at 3 years,
although there was a trend towards increased risk of disease
progression in this group when examined at earlier time
points within the ﬁrst year after transplantation. This may
suggest that achieving complete donor T lymphocyte
chimerism and maximizing the GVL effect has a larger
impact in maintaining remission in CR1/CR2 patients. This is
in contrast to non-CR1/CR2 patients, where the diminished
predictive value of T lymphocyte chimerism suggests that
the presence of active disease at the time of transplantation
poses a greater risk for relapse than delayed immune
reconstitution with donor T lymphocytes. The fact that
chronic GVHD, when analyzed as a time-dependent variable,
was a signiﬁcant predictor of disease progression only in the
CR1/CR2 patients lends further support to this idea.
The role of mixed T lymphocyte donor chimerism in
predicting AML relapse after transplantation has been
controversial, although no previous studies have stratiﬁed
patients based on disease status at transplantation as in the
current analysis. Four studies have reported no association of
mixed T lymphocyte chimerism and disease recurrence,
although 3 of these studies contained different preparative
regimens and very heterogeneous disease populations,
including acute and chronic leukemias of both myeloid and
lymphoid lineages [27,35,38]. However, the potential
importance of T lymphocyte chimerism in predicting disease
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a large analysis by Koreth et al., mixed total donor cell and T
lymphocyte chimerism < 90% at day þ30 and day þ100
in patients who underwent allo-HSCT was predictive of
increased risk of relapse, with day þ100 total donor cell
chimerism most predictive [39]. Two additional studies
have also described the signiﬁcance of day þ30 mixed T
lymphocyte chimerism in predicting disease relapse. Saito
et al. reported that T lymphocyte chimerism < 90% at
dayþ30 portended poor outcomes in a cohort of 117 patients
with both myeloid and lymphoid malignancies who under-
went busulfan-based reduced-intensity conditioning allo-
HSCT [36]. Finally, day þ30 mixed whole blood and T
lymphocyte chimerism were predictive of early relapse and
shorter overall survival in a cohort of 121 patients with
myeloid and lymphoid malignancies when chimerism was
assessed as a continuous variable [40]. In this particular
model, T lymphocyte chimerism was a stronger predictor of
relapse and overall survival compared with whole blood
chimerism testing. Likewise, the current study also supports
the value of T lymphocyte chimerism in predicting relapse
in AML/MDS after allo-HSCT, although its applicability is
limited to patients who are alive and without disease pro-
gression at day þ120. This represented 78% of all AML/MDS
patients who initially underwent allo-HSCT in our study.
However, assessing the predictive impact of dayþ90 toþ120
chimerism analysis may have particular therapeutic rele-
vance if prophylactic DLIs are considered, as the timing
usually corresponds to the tapering of immunosuppression
after allo-HSCT. As a result, prophylactic DLIs given during
this time period may be more tolerable with lower rates of
GVHD, compared with earlier administration [41].
Given the emergence of multiparameter ﬂow cytometry
(MFC) and reverse transcriptase-quantitative polymerase
chain reaction (RT-qPCR) as highly sensitive tools in assess-
ingminimal residual disease (MRD),1 limitation of this study
is the lack of MRD data that was incorporated in this analysis
[42,43]. The value of MRD testing to predict relapse after
transplantation is being actively studied. Relapse can occur if
residual clonogenic leukemia cells are present in the absence
of an effective GVL immune effect. Indeed, integration of
chimerism datawithMFC or RT-qPCRMRDmeasurements to
develop relapse risk models may represent the most prac-
tical use of such data [44]. Chimerism data remain a potential
useful tool in assessing relapse risk in subsets of patients
who may not have speciﬁc molecular markers to monitor by
RT-qPCR [42]. Moreover, although almost all AML patients
will have an identiﬁable leukemia-associated immunophe-
notype at the time of diagnosis with MFC [45], changes in
leukemia-associated immunophenotype expression patterns
at the time of relapse can occur in up to 80% to 90% of pa-
tients [46,47] which represents 1 limitation of such testing.
Identifying AML/MDS patients at high risk for impending
disease relapse in the post-transplantation setting remains a
challenge. In this large analysis, we demonstrate that mixed
T lymphocyte chimerism at day þ90 to þ120 after trans-
plantation is a promising approach of detecting patients at
higher risk for disease recurrence, and its interpretation
depends on disease status at transplantation. Chimerism
assessment should be considered with the disease risk index,
MRD assessment, and potentially other factors in identifying
patients at high risk of relapse. Strategies to enhance early
full donor T cell chimerism after transplantation and early
preemptive therapies need assessment to prevent relapse
in high-risk patients, such as immune modulation, DLI,or initiation of hypomethylating agents or tyrosine kinase
inhibitors. These approaches warrant study in prospective
clinical trials.ACKNOWLEDGMENTS
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